Clofazimine does not lead to significant QT interval prolongation: a multicentre study. Issue 5 (1st November 2018) - Zweijpfenning, Sanne M.H.
We read with great interest the article by Pontali et al. [1], entitled "Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence". In response to this paper and the debate on potential QTc prolongation in clofazimine- and bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) treatment regimens [2, 3], we assessed QTc prolongation during clofazimine use in treatment of disease caused by nontuberculous mycobacteria (NTM). This is important as NTM disease treatment typically includes multiple potential QTc-prolonging antibiotics, including macrolides, fluoroquinolones and, increasingly, clofazimine [4]. Clofazimine does not lead to significant QT interval prolongation in the treatment of nontuberculous mycobacteria http://ow.ly/sXC330lIbI8